Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA5 Device

Key Inclusion Criteria:

Subjects meeting all inclusion criteria will be considered for enrollment in the study.

1. Age 22 to 85 years.

2. Informed consent was obtained from subject or acceptable subject surrogate (e.g.,next of kin, or legal representative).

3. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.

4. Baseline NIHSS obtained prior to procedure ≥ 8 points and ≤ 25 points.

5. Pre-ictal mRS score of 0,1 or 2.

6. Treatable within 24 hours of symptom onset, defined as point in time when thesubject was last observed to be asymptomatic; treatment start is defined by arterialpuncture time.

7. If indicated, thrombolytic therapy shall be initiated per the institution's usualcare and the most recent version of the AHA/ASA Guidelines. Subjects eligible for IVthrombolysis should receive it without delay.

8. Occlusion (eTICI ≤ 1 flow) of the terminal carotid artery, middle cerebral artery M1segment or, dominant or proximal M2 segment, indicated for mechanical thrombectomy,confirmed with conventional angiography or CTA/MRA.

9. Imaging criteria:

• Perfusion weighted criterion: volume of diffusion restriction visually assessed ≤ 50 mL on CTP/MRP, or

• CT criterion: Alberta Stroke program early CT score (ASPECTS) 6 to 10 onbaseline CT/DWI-MRI.

10. The subject is indicated for a neurovascular thrombectomy procedure with an approvedstent retriever per its Instructions for Use.

Key Exclusion Criteria:

Subjects who meet any of the exclusion criteria will be ineligible for participation in the study.

The following exclusion criteria will be assessed pre-operatively:

1. Subject was diagnosed with a stroke in the past year.

2. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.

3. Known hemorrhagic diathesis, coagulation factor deficiency, oral anticoagulanttherapy with antivitamin K, with INR >3.0, or thrombocytopenia - baseline plateletcount < 50,000 platelets/mL.

4. Known baseline glucose of <50 mg/dL or >400 mg/dL.

5. Severe, sustained uncontrolled hypertension refractory to treatment (systolic bloodpressure >185 mmHg or diastolic blood pressure >110 mmHg).

6. Serious, advanced, or terminal disease with anticipated life expectancy of less than 1 year.

7. Known cancer with metastases.

8. History of life-threatening allergy (more than rash) to contrast medium.

9. Known renal insufficiency with creatinine ≥3 mg/dL or glomerular filtration rate (GFR) <30 mL/min.

10. Subject is a current user or has a recent history of cocaine &/or heroin use.

11. Known pregnancy and/or lactating female.

12. Subject is participating in a concurrent study involving an investigational drug ordevice that would impact the primary endpoint of this study.

13. Subject is unlikely to be available for a 90-day follow-up (e.g. no fixed homeaddress, visitor from overseas, etc.)

14. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).

15. Significant mass effect with midline shift.

16. Evidence of intracranial tumor (except asymptomatic meningioma of ≤ 2cm indiameter).

17. Suspicion of aortic dissection, presumed septic embolus, or suspicion of bacterialendocarditis.

18. History of preexisting stent proximal to or at the occlusion site that may precludesafe deployment or recovery of the stent retriever.

19. Vessel tortuosity too difficult to allow endovascular access of the intracranial ICAper investigator judgement. Indicators of vessel tortuosity include but are notlimited to the presence of carotid loops and type 3 aortic arches.